- Home
- RLMD vs IMNN Comparison
RLMD vs IMNN Comparison
Compare RLMD & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLMD
- IMNN
- Stock Information
- Founded
- RLMD 2004
- IMNN 1982
- Country
- RLMD United States
- IMNN United States
- Employees
- RLMD N/A
- IMNN N/A
- Industry
- RLMD Biotechnology: Pharmaceutical Preparations
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- RLMD Health Care
- IMNN Health Care
- Exchange
- RLMD Nasdaq
- IMNN Nasdaq
- Market Cap
- RLMD 11.5M
- IMNN 12.1M
- IPO Year
- RLMD N/A
- IMNN 1985
- Fundamental
- Price
- RLMD $0.40
- IMNN $0.60
- Analyst Decision
- RLMD Hold
- IMNN Strong Buy
- Analyst Count
- RLMD 4
- IMNN 2
- Target Price
- RLMD $4.25
- IMNN $15.50
- AVG Volume (30 Days)
- RLMD 4.5M
- IMNN 237.6K
- Earning Date
- RLMD 05-12-2025
- IMNN 05-12-2025
- Dividend Yield
- RLMD N/A
- IMNN N/A
- EPS Growth
- RLMD N/A
- IMNN N/A
- EPS
- RLMD N/A
- IMNN N/A
- Revenue
- RLMD N/A
- IMNN N/A
- Revenue This Year
- RLMD N/A
- IMNN N/A
- Revenue Next Year
- RLMD N/A
- IMNN N/A
- P/E Ratio
- RLMD N/A
- IMNN N/A
- Revenue Growth
- RLMD N/A
- IMNN N/A
- 52 Week Low
- RLMD $0.24
- IMNN $0.64
- 52 Week High
- RLMD $4.47
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- RLMD 51.73
- IMNN 24.71
- Support Level
- RLMD $0.36
- IMNN $0.60
- Resistance Level
- RLMD $0.44
- IMNN $1.08
- Average True Range (ATR)
- RLMD 0.08
- IMNN 0.08
- MACD
- RLMD -0.00
- IMNN -0.02
- Stochastic Oscillator
- RLMD 26.98
- IMNN 3.12
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).